AT
Avenzo Therapeutics, Inc.
SEC filingBiotechnology · San Diego, CA
Amount raised$47.2Msold at filing
Total offering$75M$27.8M still open
Investors in the raise20count reported to the SEC
FiledSep 5, 2025first sale Aug 22, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Carl GordonDirector
Garry NicholsonDirector
Patrick MachadoDirector
Judith LiDirector
Paolo TombesiExecutive Officer
Mohammad HirmandExecutive Officer
Simeon GeorgeDirector
Scott LipmanExecutive Officer
Athena CountouriotisExecutive Officer, Director
Brian SunExecutive Officer
Jakob Dupont, M.D., M.A.Director
Executive officers, directors and promoters as listed on the Form D.